Business
Adia Nutrition Inc. Identifies Over 20 Million Potentially Improperly Issued Shares and Initiates Process to Return Shares to Treasury
Winter Park, Florida--(Newsfile Corp. - September 4, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company focused on advancing stem cell therapies for orthopedics, pain management, wound repair, and regenerative medicine, today announced that it has identified over 20 million shares that may have been improperly issued as part of an ongoing review of its historical share structure.This discovery comes from a comprehensive internal audit designed to strengthen the integrity and...
About this update from Adia Nutrition, Inc.
[{"type":"text","content":"Winter Park, Florida--(Newsfile Corp. - September 4, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a publicly traded company focused on advancing stem cell therapies for orthopedics, pain management, wound repair, and regenerative medicine, today announced that it has identified over 20 million shares that may have been improperly issued as part of an ongoing review of its historical share structure.","length":400,"tagName":"p"},{"type":"text","content":"This discovery comes from a comprehensive internal audit designed to strengthen the integrity and transparency of the company's capitalization. The shares in question were issued before the current leadership took over and lacked proper documentation or regulatory compliance.","length":280,"tagName":"p"},{"type":"text","content":"Adia Nutrition Inc. has confirmed with its legal counsel that they agree with the decision to address this matter and have filed the first case in the appropriate jurisdiction to seek the cancellation of these shares and their return to the company's treasury. This action is expected to strengthen the company's share structure without impacting ongoing operations or strategic initiatives.","length":399,"tagName":"p"},{"type":"text","content":""Our commitment to corporate governance and shareholder value remains paramount," said Larry Powalisz, CEO of Adia Nutrition Inc. "By proactively addressing these historical issues, we are taking decisive steps to rectify past discrepancies and position the company for sustained growth in the regenerative medicine sector."","length":344,"tagName":"p"},{"type":"text","content":"The company will provide updates as the legal proceedings progress and continues to focus on its core mission of advancing stem cell therapies, including","length":153,"tagName":"p"},{"type":"text","content":"Adia Nutrition will provide updates as the legal process moves forward and remains focused on its mission of advancing cutting-edge stem cell therapies, including Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Sclerosis, as well as treatments for orthopedic conditions, chronic pain, and complex wound repair.","length":334,"tagName":"p"},{"type":"text","content":"For questions, inquiries, or additional information, please contact Larry Powalisz at [email protected] or by phone at 321-788...